Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,087,640
  • Shares Outstanding, K 126,492
  • Annual Sales, $ 1,828 M
  • Annual Income, $ -440,240 K
  • 60-Month Beta 0.41
  • Price/Sales 10.39
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALNY with:

Options Overview Details

View History
  • Implied Volatility 56.65% ( +2.40%)
  • Historical Volatility 22.88%
  • IV Percentile 98%
  • IV Rank 67.99%
  • IV High 67.20% on 02/14/24
  • IV Low 34.25% on 11/22/23
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,246
  • Volume Avg (30-Day) 1,165
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 44,495
  • Open Int (30-Day) 50,052

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.23
  • Number of Estimates 11
  • High Estimate -0.84
  • Low Estimate -1.76
  • Prior Year -2.21
  • Growth Rate Est. (year over year) +44.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.98 +5.22%
on 04/25/24
155.49 -3.93%
on 05/08/24
+3.31 (+2.27%)
since 04/23/24
3-Month
141.98 +5.22%
on 04/25/24
161.31 -7.40%
on 02/27/24
-8.27 (-5.25%)
since 02/23/24
52-Week
141.98 +5.22%
on 04/25/24
218.88 -31.75%
on 07/17/23
-42.45 (-22.13%)
since 05/23/23

Most Recent Stories

More News
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 149.38 (-1.01%)
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

/CNW/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets,...

ALNY : 149.38 (-1.01%)
Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

BMO : 94.55 (+0.07%)
ALNY : 149.38 (-1.01%)
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 149.38 (-1.01%)
Alnylam: Q3 Earnings Snapshot

Alnylam: Q3 Earnings Snapshot

ALNY : 149.38 (-1.01%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

ALNY : 149.38 (-1.01%)
2 Growth Stocks That Could Rocket Higher Before the End of 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

PFE : 28.69 (-3.07%)
ALNY : 149.38 (-1.01%)
TSVT : 4.40 (-3.30%)
BMY : 41.54 (-1.89%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 361.02 (-0.75%)
ABBV : 158.26 (-0.85%)
ABCL : 3.85 (-0.26%)
ALNY : 149.38 (-1.01%)
AMGN : 306.50 (-0.94%)
ANAB : 24.96 (-0.32%)
AZN : 78.18 (-0.79%)
BMY : 41.54 (-1.89%)
INCY : 57.45 (-1.29%)
REGN : 980.57 (-0.33%)
VIE : 53.01 (unch)
3 Stocks to Buy For the COVID Resurgence

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

MRNA : 164.01 (+0.42%)
NVAX : 15.15 (-3.50%)
PFE : 28.69 (-3.07%)
ALNY : 149.38 (-1.01%)
ABUS : 3.28 (-3.81%)
BNTX : 99.00 (-3.23%)
CVAC : 3.97 (+1.53%)
LGF-A : N/A (N/A)
Alnylam: Q2 Earnings Snapshot

Alnylam: Q2 Earnings Snapshot

ALNY : 149.38 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 153.57
2nd Resistance Point 152.29
1st Resistance Point 150.83
Last Price 149.38
1st Support Level 148.09
2nd Support Level 146.81
3rd Support Level 145.35

See More

52-Week High 218.88
Fibonacci 61.8% 189.50
Fibonacci 50% 180.43
Fibonacci 38.2% 171.35
Last Price 149.38
52-Week Low 141.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar